key: cord-0755905-tnm13bmh authors: Belda, Francisco; Mora, Oscar; Lopez Martinez, Monica; Torres, Nerea; Vivanco, Ana; Christie, Rebecca; Crowley, Michael title: Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine date: 2022-04-08 journal: Vaccine DOI: 10.1016/j.vaccine.2022.04.006 sha: 2bbe3ce0876e9ed39a57007edebb7749ad0fc9b0 doc_id: 755905 cord_uid: tnm13bmh Seroconversion panels are an important tool for investigating antibody responses in acute and chronic phases of disease and development of serological assays for viral diseases including COVID-19. Globally it is anticipated that vaccines against SARS-CoV-2 will facilitate control of the current pandemic. The two COVID-19 seroconversion panels analyzed in this study were obtained from healthcare workers with samples collected before vaccination with the mRNA-1273 vaccine (Moderna) and after the first and second doses of the vaccine. Panel samples were tested for antibodies to SARS-CoV-2 (IgG). Individual subjects with a positive response for anti-SARS-CoV2 IgG in their pre-vaccination samples showed a significantly enhanced response to the first vaccination. In older subjects, lower immunological responses to the first injection were observed, which were overcome by the second injection. All subjects in the study were positive for anti-SARS-CoV-2 IgG after the second dose of vaccine. Since December 2019, COVID-19, the disease resulting from SARS-CoV-2 infection, has affected > 404 million people worldwide and caused > 5.7 million deaths. [1] Vaccines developed against SARS-CoV-2 [2, 3] have provided the healthcare community with crucial tools that can ultimately bring the pandemic under control. In this paper, the seroconversion panels with samples collected before and after 4 administration of a SARS-CoV-2 vaccine are described that demonstrate the immune response to vaccination. Seroconversion panels are serial blood samples collected before and after the antibody development in response to viral infection or vaccination. They can be useful tools in the creation of antibody assays, determination of the window period of detection, validation and quality control for development and manufacture of commercial antibody tests. Detection of viral exposure and vaccine effectiveness is a critical step in gaining control of SARS-CoV-2. The panels are also a source of welldefined neutralizing antibodies useful in investigating their effectiveness blocking new COVID-19 variants. The seroconversion panels analyzed in this study were collected from two groups of subjects before vaccination (mRNA-1273) and after the first and second doses of the vaccine. The samples were analyzed using a chemiluminescent immunoassay (CLIA) and an enzyme-linked immunosorbent assay (ELISA). The samples in these seroconversion panels were collected from consenting healthcare workers at a hospital ( [4] For the ELISA, the manufacturer showed the negative percent agreement was 99% (95% CI 97%-99%) in 480 serum samples from individual donors and the positive percent agreement was 97% (95% CI 90%-99%) for 65 samples from patients with confirmed SARS-CoV-2 (by RT-PCT) collected 15 or more days after symptoms onset. [5] Panel H was comprised of undiluted, unpreserved serum and potassium EDTAtreated plasma specimens collected from 30 subjects between 23 rd December 2020 to 15 th March 2021. The subjects were healthy adults 19-73 years old who received two injections of mRNA-1273 vaccine (100 µg -objective target 28 days apart). There were 9 male and 21 female subjects. The subjects were 29 Caucasians and one African American. Samples from this panel were tested using the CLIA. The CLIA and ELISA SARS-CoV-2 IgG assays were performed according to the manufacturers' directions. Both utilize recombinant antigens specific to SARS-CoV-2: CLIA -antigens to S1 and S2 spike protein IgGs; ELISA -antigens to S1 spike protein IgG. The specific composition of the antigens was not specified and are presumed to be nonidentical. Testing of pre-vaccination samples in Panel G (n=15 subjects) with the CLIA gave the following results (Table 1, Figure The comparison of the immunological response after the first vaccination between younger naïve subjects (<54 years; n=20; 137.4 ± 56.2 AU/mL) and older naïve subjects (≥54 years; n=15; 61.7 ± 78.0 AU/mL) showed a significant difference (p=0.0024) using results from both panels. Convalescent subjects were not included in this analysis since the aim was to assess any age-related difference in antibody generation and these subjects had antibodies present before vaccination. Moreover, seven of the 15 older naïve subjects did not generate an immune response after the first vaccination while all the younger naïve subjects generated an immune response. The measurement of IgG levels is a crucial tool in monitoring and controlling the spread of COVID-19 and in determining medication and vaccine effectiveness. Detection of antibodies by immunoassay is useful for the verification of humoral immunity whether due to past infection, passive immunity (e.g., convalescent plasma or monoclonal antibodies) or vaccination. [8] [9] [10] This increased response to the first vaccine has been linked to an increased level of SARS-CoV-2 antigen specific memory B cells. [8] The antibody response to the first vaccination in subjects with positive prevaccination samples (convalescent subjects) was of the same magnitude as that obtained with the second vaccine dose in subjects without previous COVID-19 infection (naïve subjects). This finding supports prioritizing vaccine administration based on serostatus during the current global vaccine shortage, thus maximizing coverage and effectiveness of current supplies. [9] [10] [11] Panel G was analyzed with both the CLIA and ELISA with similar results. This suggests that these seroconversion panels could be useful for comparing different immunoassays for accuracy and congruence to determine which is the most useful for a particular application. Limitations of this study include the number of subjects studied and a racially homogenous (almost entirely white) and predominantly female population. This could limit generalization of the results to wider populations and under-represented groups. Another limitation is that the detection assays used are not neutralizing antibodies assays that would detect virus blocking antibodies. Furthermore, it would be interesting to determine the presence of specific antibodies against different antigenic parts of the virus than S1 and S2 spike proteins (e.g. nucleocapsid protein), in the group of post-vaccination samples from COVID-19 convalescent subjects. In conclusion, these seroconversion panels demonstrate the appearance of were considered positive; values greater than the assay range (up to 400 AU/mL) were recorded as 400 AU/mL due to the upper limit of detection. Significant differences were seen between naïve and convalescent subjects in pre-vaccine and post-vaccine: first dose samples (p<0.0001). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Liaison SARS-CoV-2 S1/S2 IgG: The full automated serology test for the detection of SARS-CoV-2 IgG antibodies Anti-SARS-CoV-2 (immunoglobulin G) ELISA kit, a sensitive and specific assay for the detection of human anti-SARS-CoV-2 immunoglobulin G antibodies Guidance for industry and FDA Staff: Class II special controls guidance document: Hepatitis A serological assays. US Food and Drug Administration, Center for Devices and Radiological Health Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in recovered COVID-19 subjects One dose of SARS-CoV-2 vaccines exponentially increases antibodies in recovered individuals with symptomatic COVID-19 ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Francisco Belda, Oscar Mora, Monica Lopez Martinez and Nerea Torres are employees of Grifols. Rebecca Christie and Michael Crowlet are employees of Access Biologicals.